Lantern Pharma shares fall 6.72% intraday despite positive clinical trial results.

Lantern Pharma Inc. declined 6.72% in intraday trading. The company reported operational highlights and financial results for the second quarter of 2025, noting complete responses in patients across two of its clinical trials. This news should be considered bullish, but the stock price movement suggests that investors may be reacting to other factors not mentioned in the news events provided.